(BUSINESS WIRE) Edwards Lifesciences agreed to acquire JenaValve Technology and Endotronix on Wednesday, adding to their structural heart portfolio. JenaValve has been a leader in studying aortic regurgitation and Edwards plans to further this research. This will include the new JenaValve Trilogy Heart Valve System, which is expected to receive U.S. Food and Drug Administration (FDA) approval in late 2025. Endotronix specialized in the treatment of heart failure and investigated both in-hospital and at-home management for patients. Edwards expects the transaction will take place in 2025 and cost $1.2 billion. “We are pleased to enter these structural heart therapeutic areas with innovation, world-class science and clinical evidence to provide access to life-saving technologies for patients around the world,” said Bernard Zovighian, CEO of Edwards, in a statement published Wednesday online. Image Credit: M Stocker – stock.adobe.com